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Abstract
Background: Hypoxia is a hallmark of the solid tumor microenvironment and is associated with poor outcomes in
cancer patients. The present study was performed to investigate mechanisms underlying the hypoxia-induced
phenotypic changes using human malignant mesothelioma (HMM) cells.
Methods: Hypoxic conditions were achieved by incubating HMM cells in the air chamber. The effect of hypoxia on
phenotype changes in HMM cells was investigated by performing in vitro clonogenicity, drug resistance, migration,
and invasion assays. Signaling pathways and molecules involved in the more aggressive behaviors of HMM cells under
hypoxia were investigated. A two-tailed unpaired Student’s t-test or one-way ANOVA with Bonferroni post-test correction
was used in this study.
Results: Hypoxic conditions upregulated hypoxia-inducible factor 1 alpha (HIF-1α) and HIF-2α in parallel with the
upregulation of its target, Glut-1, in HMM cells. In vitro clonogenicity of HMM cells was significantly increased in
hypoxic conditions, but the proliferation of cells at a high density in hypoxia was lower than that in normoxic
conditions. The expression levels of HIF-2α and Oct4 were increased in hypoxic HMM cells. The percentage of
cells with high CD44 expression was significantly higher in HMM cells cultured in hypoxia than those cultured in
normoxia. Hypoxia significantly enhanced the resistance of HMM cells to cisplatin, which occurred through
cytoprotection against cisplatin-induced apoptosis. While cisplatin treatment decreased the ratio of Bcl-2 to Bax
in normoxic condition, hypoxia conversely increased the ratio in HMM cells treated with cisplatin. Hypoxia increased
the mobility and invasiveness of HMM cells. Epithelial to mesenchymal transition was promoted, which was indicated
by the repression of E-cadherin and the concomitant increase of vimentin in HMM cells.
Conclusions: The data illustrated that hypoxic conditions augmented the aggressive phenotypes of HMM cells at the
biological and molecular levels. The present study provides valuable background information beginning to understand
aggressiveness of HMM in tumor microenvironments, suggesting that a control measure for tumor hypoxia may be an
effective therapeutic strategy to reduce the aggressiveness of cancer cells in HMM patients.
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Background
Hypoxia is a common feature of tumor microenvironment
[1]. There are two types of hypoxia in solid tumors, inter-
mittent hypoxia and chronic hypoxia. Intermittent hyp-
oxia results from abnormal blood flow associated with
transient fluctuations in tumor perfusion and the high
permeability of tumor vessels with interstitial hyperten-
sion [2]. Chronic hypoxia arises due to the inability of the
vascular system to supply the growing tumor mass with
adequate amounts of oxygen [3]. Both types of tumor hyp-
oxia have been reported to be correlated with poor out-
comes in many cancer patients [4]. Hypoxia enhances
cancer cell survival, metastasis, and drug resistance in
multiple tumor types [1, 4].
One of the adaptive cellular responses to hypoxia is
to increase the expression of hypoxia-inducible factor
alpha (HIFα), a subunit of the heterodimeric transcrip-
tion factor HIF [5]. In normoxia, the HIFα subunit is
hydroxylated by prolyl hydroxylases (PHD) and recog-
nized by an E3 ubiquitin ligase, von Hippel-Lindau
protein, which proteasomally degrades the HIFα pro-
tein [6]. Under hypoxia, however, HIFα becomes stable
and starts to accumulate in cancer cells by blocking
the von Hip-mediated ubiquitin-proteasome pathway
[6]. HIFα heterodimerizes with HIF-1β and migrates to
the nucleus. The heterodimer recognizes and binds the
hypoxia-responsive element located in the promotor of
hundreds of genes [6]. Transcriptional activity of HIF
in cancer cells is largely mediated by HIF-1α and
HIF-2α [7]. The function of HIF-1α has been exten-
sively investigated in nearly every stage of tumor pro-
gression [8]. Recently, growing evidence has suggested
that HIF-2α is also a critical mediator of aggressive
cancer phenotypes including metastasis and dediffer-
entiation [9]. Although HIF-1α and HIF-2α activate
numerous hypoxia-induced genes harboring HIF bind-
ing motifs, each HIFα subunit has its own preferential
targets. For example, HIF-1α induces genes primarily
involved in anaerobic glycolysis, angiogenesis, and
apoptosis [3, 8]. On the other hand, HIF-2α regulates
genes that promote invasion and stemness [9, 10]. De-
pending on tumor types or hypoxic duration, the HIFα
isoforms are mutually cooperative or exclusive for bio-
logical functions and phenotypes [7].
Human malignant mesothelioma (HMM) is an ag-
gressive malignancy arising from the mesothelium on
the surface of the body cavity [11]. Exposure to asbestos
fibers increases the risk of HMM, but simian virus 40
may also have a role in HMM tumorigenesis [11]. The
occurrence rate of HMM is anticipated to increase
worldwide [12]. HMM is highly resistant to traditional
anticancer drugs [13]. Several mechanisms of drug re-
sistance have been proposed in HMM, including drug
transporters, anti-apoptosis, and antioxidant defenses
[14]. Despite the advances in systemic chemotherapy
using an antifolate-platinum regimen have improved
clinical outcomes in HMM patients, overall prognosis
remains poor with median survival times of 4 to
13 months from the initial diagnosis [15, 16].
The existence of hypoxic cells within a tumor is asso-
ciated with modulation of the malignant process in
many cancers [1, 5]. Recent studies have revealed that
HMM contains hypoxic regions, suggesting a potential
link between tumor hypoxia and ineffective therapeutic
efficacy [17, 18]. However, the mechanism underlying
the effect of hypoxia on HMM remains largely unknown.
The present study showed that hypoxia promotes ag-
gressive phenotypes of HMM cells. Hypoxia enhances in
vitro clonogenicity, migration, invasion, and drug resist-
ance through inhibition of apoptosis in HMM cells.
Various signaling networks and molecular candidates
were suggested for the aggressive biological behaviors of
HMM cells, including HIF-1/2α and Oct4 signaling
pathways, epithelial to mesenchymal transition (EMT),
and Bcl-2 regulation. Exploiting tumor hypoxia may be
an alternative therapeutic strategy to reduce the aggres-
sive behavior of HMM cells.
Methods
Cell culture and cell lines
MS1 and H513 cell lines were kindly provided by Dr.
Jablons (University of California, San Francisco) and Dr. R
Kratzke (University of Minnesota), respectively. The cell
lines were cultured in RPMI 1640 medium (Mediatech
Inc., Manassas, VA, USA) containing 10% fetal bovine
serum (FBS; Mediatech Inc.), 10 mM of glucose, 10 mM
of HEPES (Sigma-Aldrich, St. Louis, MO, USA), 1.5 g/L
sodium bicarbonate (Sigma-Aldrich), 1 mM of sodium
pyruvate (Sigma-Aldrich), and 100 U/100 μg/mL penicil-
lin/streptomycin (Gibco-Life Technology, Gaithersburg,
MD, USA) at 37 °C in a humidified atmosphere containing
5% CO2. To establish a glucose-starved condition, HMM
cells were cultured in DMEM medium (Gibco-Life Tech-
nology) supplemented with 0 or 1 mM of D-(+)-glucose
(Sigma-Aldrich). The HMM cell lines were determined to
be free of mycoplasma contamination by using e-Myco
Mycoplasma PCR detection kit (e-Myco, iNtRON
Biotechnology, Sungnam, Korea).
Hypoxic condition
Hypoxia was generated by infusing a pre-analyzed air
mixture (2.2% O2/5% CO2/92.8% N2) at a flow rate of
5 L/min for 15 min into an air chamber (Billups-Rothen-
berg Inc., Del Mar, CA, USA) with inflow and outflow
valves. Hypoxic treatment of cells was achieved by incu-
bating the cells in the air chamber maintained in a hu-
midified environment at 37 °C. The culture medium was
replaced just before carrying out hypoxic treatment.
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Cell proliferation and cytotoxicity assay
Cell proliferation was determined by counting the number
of cells and measuring cell metabolic activity using a
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium brom-
ide (MTT) dye in each well at defined intervals. Cells were
seeded on 6-well plates or 96-well plates at a different dens-
ity per well. For cell proliferation by manual counting and
MTTassay, each group was replicated in five and six separ-
ate wells, respectively. The following day, the cells were
subjected to normoxia or hypoxia for the indicated periods
either without drugs or with varying concentrations of cis-
platin (Dong-A Pharm, Seoul, the Republic of Korea). For
cytotoxicity assay, each group was replicated in three separ-
ate wells. After the treatment, the cells were enumerated
using a hemocytometer under an Olympus CK2 micro-
scope (Optical Co., Ltd., Tokyo, Japan). After incubation in
MTT dye (5 mg/mL) for 2 h at 37 °C, protected from the
light, the absorbance values were determined at 570 nm by
the microplate reader (Gen5, Epoch, Bio Tek, Winooski,
VT, USA). The absorbance from untreated control cells
under each normoxic and hypoxic condition was consid-
ered representative of 100% cell viability. All other mea-
surements were expressed as a percentage of the control
cell value ± standard deviation.
Clonogenicity assay
To prevent cell to cell contact or the overlapping of too
many colonies, 200 cells were chosen to seed on 6-well
plates, as previously described [19]. Each group was rep-
licated in four separate wells. When attached to the
plate, the cells were subjected to incubation for 48 h
under normoxia or hypoxia. After the incubation, the
culture medium was replaced, and the cells were further
incubated at 37 °C for 5 days. The cells were fixed with
methanol for 5 min, stained with Diff-Quik solution
(Merck, Darmstadt, Germany), and dried. Groups of
more than 50 cells were counted as viable colonies. The
colony forming ability was determined by calculating the
percentage of surviving cells based on the plating effi-
ciency that is a ratio of the number of colonies to the
number of cells seeded [19].
Wound healing assay
HMM cells were seeded on 24-well plates at cell dens-
ities of 105 cells per well in triplicate. When the cells
reached 90% confluence, the culture medium was re-
placed with one containing mitomycin C (Sigma-Al-
drich) at a final concentration of 2 μg/mL, followed by
further incubation for 2 h. Mitomycin C was used to
minimize the proliferative effect of cancer cells, and the
concentration used in this study was found to be
non-cytotoxic [20]. The cell monolayer was manually
scratched with a 1000 μl pipette tip. The cells were sub-
jected to further incubation in normoxia or hypoxia for
48 h. The area of the scratch distance was photographed
under a phase contrast microscope using an Olympus
CK2 camera (Optical Co.) at 0 and 48 h of incubation.
Cell migration was determined by measuring the migra-
tion distance. The results were normalized to the initial
scratch distance and presented as % with the normoxic
condition set at 100%.
Invasion assay
The 24-transwell plates (8.0 μm pore size with
poly-carbonate membrane; Corning Costar, Lowell, MA,
USA) covered with 2 mg/ml basement membrane Matrigel
matrix (BD Biosciences, Bedford, MA, USA) were used for
the invasion assay. Each group was replicated in three sep-
arate wells. The coated transwell was hydrated with culture
medium for 2 h prior to cell seeding. HMM cells were re-
suspended in serum-free medium and seeded at a cell
density of 2.5 × 104 into the upper invasion chamber. Cul-
ture medium containing 10% FBS was then added to the
lower chamber. The cells were incubated at 37 °C for 24 h
under normoxia or hypoxia. After a day of incubation, the
cells that had invaded the lower surface of the membrane
were fixed with methanol for 5 min, stained with Diff-Quik
solution (Merck), and quantified by counting five random
fields using a phase contrast microscope. Invasion was
expressed as the ratio of invading cells incubated under
hypoxia compared to the controls in normoxia.
Apoptosis assay
HMM cells were seeded on 60 mm2 petri dishes with
confluency of 60% density in quadruplicate. On the fol-
lowing day, the cells were incubated in normoxia or hyp-
oxia for 48 h either with or without cisplatin (10 μM).
After the incubation, apoptosis was evaluated using the
Annexin V-FITC apoptosis detection kit (Komabiotech,
Inc., Seoul, Korea). Briefly, cells were harvested, washed,
and incubated in binding buffer containing a saturating
concentration of FITC-conjugated Annexin V in the
dark for 15 min at room temperature. After being
washed with a binding buffer, the cells were resuspended
and incubated with 500 μl of binding buffer containing
10 μl of propidium iodide (PI) on ice. The cells were im-
mediately analyzed for the fluorescence of fluorescein
isothiocyanate (FITC) and PI using flow cytometry
(Becton Dickinson, San Jose, CA, USA). Cells undergo-
ing early and late apoptosis were determined.
Cell cycle analysis
HMM cells were plated on 6-well plates at confluency of
50% density in triplicate. After a day of incubation, the cells
were subjected to normoxia or hypoxia for 24 and 48 h. At
the indicated time points, cells were harvested and fixed
with ice-cold 70% ethanol for 2 h at − 20 °C. After being
washed with PBS, the cells were incubated with PI/RNase
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staining buffer (BD Pharmingen, BD Biosciences) for
15 min at room temperature. The cells were immediately
subjected to analysis using a flow cytometer (BD Biosci-
ences) for the determination of their DNA contents.
Measurement of cell surface CD44 expression
HMM cells were plated on 6-well plates in triplicate. After
48 h of hypoxia incubation, HMM cells resuspended in
PBS were incubated with primary antibody against CD44
(Genetex, CA, USA) at 4 °C for 1 h in the dark. Secondary
antibody goat anti-rat IgG-PE (Santa Cruz, CA, USA) for
CD44 analysis was incubated at room temperature for
30 min in the dark. After washing with PBS, HMM cells
were resuspended in PBS and subjected to flow cytometric
analysis for CD44 expression. Unstained cells were used
to gate on live cells. After excluding cell debris from the
gated populations, a minimum of 10,000 events per condi-
tion were collected for the analysis.
Western blot analysis
After washing cells with cold PBS twice, cell lysates were
obtained using RIPA lysis buffer containing complete
protease inhibitors. The same amounts of protein were
subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis; subsequently, the protein bands were
transferred onto a nitrous membrane by a wet transfer
apparatus. After blocking with 5% non-fat milk at room
temperature for 60 min, the nitrous membrane was
placed in 0.1% Tween 20 PBS (T-PBS) containing pri-
mary antibodies including HIF-1α (1:1000, Cell Signal-
ing), HIF-2α (1:1000, Cell Signaling), E-cadherin (1:1000,
Cell Signaling), Bcl-2 (1:1000, Cell Signaling), Bax
(1:1000, Cell Signaling), Bcl-xL (1:1000, Cell Signaling),
Oct4 (1:1000, Cell Signaling) and vimentin (1:1000, Cell
Signaling) and incubated overnight at 4 °C. An antibody
against β-actin (1:1000, Cell Signaling) was used as a
loading control. After the blot was washed with T-PBS
three times for 10 min each, peroxidase-labeled second-
ary anti-rabbit or anti-mouse antibodies (1:2000) were
applied to the blot for 90 min. The protein levels were
detected on CL-Exposure film with the use of enhanced
chemiluminescence detection reagents (Advansta, Menlo
Park, CA, USA) according to the manufacturer’s instruc-
tions. Densitometric analysis was performed using the
ImageJ program (http://rsbweb.nih.gov/ij).
Gene expression and quantitative real-time PCR
Total RNA was isolated from the HMM cell lines using the
RNeasy Plus Mini Kit protocol (Qiagen, Valencia, CA,
USA). The quality and quantity of the total RNA were
assessed using Nanodrop (Nanodrop Technologies, Wil-
mington, DE, USA). Total RNA of 500 ng was used to
synthesize cDNA using QuantiTect Reverse Transcription
Kit (Qiagen, Valencia, CA, USA). Quantitative real-time
PCR was performed using the Rotor-Gene SYBR Green
RT-PCR Kit (Qiagen, Valencia, CA, USA). PCR conditions
were as follows: 1 cycle at 95 °C for 10 min, followed by
45 cycles of 95 °C for 10 s, and then 60 °C for 30 s. The ex-
pression level of each gene was normalized based on en-
dogenous GAPDH expression. The analysis of relative gene
expression was determined according to the 2−ΔΔCt
method, as previously described [21]. The primer sequences
used in this study are listed in Additional file 1.
Statistical analysis
All data were presented as the means ± standard devi-
ation. Statistical analyses were done using Microsoft
Excel (Microsoft, Seattle, WA, USA) and SPSS software
(IBM, Armonk, NY, USA). P values were calculated by a
two-tailed unpaired Student’s t-test or one-way ANOVA
with Bonferroni post-test correction. The results were
confirmed in at least three independent experiments and
considered to be statistically significant when P value
was less than 0.05. All dataset and the statistical infor-
mation are listed in Additional file 2.
Results
Experimental induction of hypoxia in vitro
Experimental establishment of hypoxia was verified by
HIFα induction in HMM cells. Western blot analysis
confirmed the upregulation of HIF-1α and the de novo
synthesis of HIF-2α under hypoxia (Fig. 1a). As
Fig. 1 The experimental establishment of tumor hypoxia in HMM cells. (a) Hypoxia markedly increased HIF-1α expression and induced HIF-2α
expression de novo in HMM cells. (b) A HIF-1/2α target Glut-1 increased in response to hypoxia and glucose starvation in MS1 cells. Abbreviations: N,
normoxia; H, hypoxia
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hypoxia was prolonged, HIF-1/2α target Glut-1 expres-
sion was also elevated, suggesting a functional tran-
scriptional activity of HIF-1α in the hypoxic state
(Fig. 1b). Glucose starvation was used as a positive
control for Glut-1 expression.
Hypoxia enhanced in vitro clonogenicity but reduced
proliferation of HMM cells
The plating efficiency of the untreated control was ap-
proximately 0.6 in HMM cells. Hypoxia significantly in-
creased the surviving fraction by 34% and 37% in MS1
and H513 cells, respectively, compared to that of nor-
moxic cells (Fig. 2a). Because the ability of tumor cells to
form a single colony is related to the acquisition of stem-
ness properties, the levels of a variety of stemness genes
were investigated. Among them, Oct4 gene expression
was significantly increased in HMM cells under hypoxia
(Fig. 2b). The Oct4 protein was also significantly elevated
under hypoxia (Fig. 2c). We also attempted to determine
cell surface markers that correlate with stem cell signa-
tures, and hypoxia was found to significantly increase the
percentage of HMM cells with the high CD44 expression,
a putative marker of cancer stemness of HMM
(Additional file 3) [22, 23]. On the other hand, chronic
hypoxia did not enhance the proliferative capacity of
HMM cells. As the cell density increased, an inhibitory ef-
fect of hypoxia on cell growth was detected (Fig. 3a). The
parallel measurement using MTT dye also confirmed the
significant reduction in cell proliferation of HMM cells
under hypoxia. The absorbance-based cell viability was de-
creased after 48 h of hypoxia from the initial seeding
density of 1000 and 5000 in MS1 and H513 cells, respect-
ively (Fig. 3b). The reduced proliferation under hypoxia
was not attributable to the cell cycle arrest at the G1/0
phase (Fig. 3c). The data indicated that hypoxia improved
single cell survivability that was mediated through stem-
ness acquisition in HMM cells.
Hypoxia induced drug resistance in HMM cells
In the normoxic state, cisplatin treatment decreased the
cell viability of HMM cells in a dose-dependent manner,
but hypoxia significantly reduced the sensitivity of the
cells to the drug (Fig. 4). Because apoptosis has been
used for the evaluation of the chemotherapeutic efficacy
of cisplatin [14], a bivariate Annexin V/PI analysis was
performed. Compared to the apoptosis of cells exposed
to cisplatin in normoxia, hypoxia not only decreased
apoptosis in HMM cells without cisplatin treatment but
also significantly inhibited cisplatin-induced apoptosis
(Fig. 5a). The expression levels of representative pro-
and anti-apoptotic Bcl-2 family members were deter-
mined by immunoblot analysis. As shown in Fig. 5b, the
Bcl-2 level was increased in HMM cells under the hyp-
oxic state compared to the level in HMM cells under
normoxic conditions. However, the level of Bcl-xL
remained almost unchanged in hypoxic MS1 cells, and
the increase of Bcl-xL was much less in hypoxic H513
cells, compared to that in normoxic H513 cells. A
Fig. 2 The effect of hypoxia on in vitro clonogenicity in HMM cells. (a) Hypoxia enhanced the colony forming ability of HMM cells. Representative
microscopic examinations are presented. P value was calculated by Student’s t-test. Hypoxia significantly upregulated the expression of Oct4 at
transcriptional (b) and translational (c) levels in HMM cells. P value was calculated by one-way ANOVA with Bonferroni post-test. *P value < 0.05,
**P value < 0.01. Abbreviations: N, normoxia; H, hypoxia
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Fig. 3 The effect of hypoxia on cell proliferation in HMM cells. Hypoxia significantly decreased proliferation and viability in HMM cells at high cell
seeding density. (a) Counting cell numbers. (b) MTT assay. The number of cells initially seeded is presented in parentheses. Cell cycle profiles did
not appreciably differ between normoxic and hypoxic HMM cells (c). *P value < 0.05, **P value < 0.01, as calculated by Student’s t-test. Abbreviations:
N, normoxia; H, hypoxia
Fig. 4 The effect of hypoxia on drug sensitivity in HMM cells. MTT assay. The sensitivity to cisplatin was decreased in HMM cells under hypoxia
for 24 h (a) and 48 h (b), compared to the sensitivity of those in normoxia. * indicates a significant difference compared with the corresponding
normoxic cisplatin-treated control. *P value < 0.05, **P value < 0.01, as calculated by Student’s t-test
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profound elevation of Bax expression was detected in
hypoxic MS1 cells, but it remained almost unchanged in
H513 cells. Due to the high Bax expression under hyp-
oxia, the ratio of either Bcl-2 or Bcl-xL to Bax was de-
creased in MS1 cells. The Bcl-2 to Bax ratio remained
increased in H513 cells following hypoxia, but the in-
crease in the ratio of Bcl-xL to Bax was not significant.
Figure 5c shows the expression profiles of the Bcl-2,
Bcl-xL, and Bax in HMM cells treated with cisplatin. In
the normoxic state, cisplatin reduced the expression of
Bcl-2, but hypoxia increased and maintained the Bcl-2
expression in HMM cells treated with cisplatin. With
cisplatin treatment, Bcl-xL expression was decreased in
HMM cells as hypoxia was prolonged. The densitometric
analysis confirmed the upregulation of Bax expression
following cisplatin treatment in MS1 cells. The extent of
increase in Bax expression was diminished in hypoxic
MS1 cells, compared to the level of MS1 cells in nor-
moxia. While the Bcl-2 to Bax ratio decreased in the
normoxic state following cisplatin treatment, hypoxia in-
creased the ratio. The Bcl-xL to Bax ratio was lowered
in hypoxic HMM cells treated with cisplatin, compared
to that of HMM cells treated with cisplatin in normoxia.
Taken together, these results indicated that hypoxia pro-
moted the resistance of HMM cells to cisplatin by regu-
lating Bcl-2 family members.
Hypoxia enhanced migration, invasion, and epithelial to
mesenchymal transition of HMM cells
In the wound healing assay, HMM cells in hypoxia dis-
played a smaller gap distance than did cells under nor-
moxia (Fig. 6a). Under hypoxia, H513 cells showed
increased invasiveness (Fig. 6b). The H513 cells were
round to oval or occasionally polygonal with a small
amount of cytoplasm, showing high nucleus to cytosol
ratio. The MS1 cells were generally spindle to polygonal
(Fig. 6c). The HMM cells exposed to hypoxia under-
went a morphologic change, showing a neuron-like ap-
pearance characterized by pseudopodia protrusions
(Fig. 6c). To investigate the mechanisms underlying
hypoxia-induced cell migration, the expression levels of
two representative EMT-related markers, E-cadherin
and vimentin, were analyzed. Western blot analysis
revealed that hypoxia reduced the expression of
E-cadherin and concomitantly increased the expression
of vimentin in HMM cells (Fig. 6d). Vimentin was up-
regulated in MS1 cells, but E-cadherin was not de-
tected. It might be due to the infrequent expression of
E-cadherin in HMM cell lines or primary tumors with
mesenchymal cell phenotype [21]. These results showed
that hypoxia enhances the acquisition of migratory and
invasive phenotypes that are associated with the EMT
process in HMM cells.
Fig. 5 The effect of hypoxia on cisplatin-induced apoptosis in HMM cells. (a) Hypoxia significantly reduced apoptosis either with or without
cisplatin in HMM cells. (b) Hypoxia upregulated the expression of anti-apoptotic Bcl-2, whereas Bcl-xL levels remained almost unchanged in HMM
cells. Marked increase in pro-apoptotic Bax expression was detected in MS1 cells only. The ratio of Bcl-2 and Bcl-xL to Bax increased in H513 cells.
(c) Hypoxia increased Bcl-2 levels and maintained the expression during exposure to cisplatin treatment in HMM cells, compared to the expression
level in cells in normoxia. With cisplatin treatment, Bcl-xL expression either tended to decrease or remained unchanged in HMM cells under hypoxia,
compared to the level in cells in normoxia. The cisplatin-induced increase in Bax expression was less under hypoxia than under normoxia in MS1 cells.
The Bcl-2 to Bax ratio increased in HMM cells under hypoxia following cisplatin. All protein expression was normalized to endogenous β-actin level
and is presented as densitometric values at the top of each protein blot. *P value < 0.05, as calculated by one-way ANOVA with Bonferroni post-test
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Discussion
Tumor cell adaptation to hypoxic condition leads to
cancer progression [1, 2, 5]. The present study demon-
strates that hypoxia causes HMM cells to behave more
aggressively at the biological and molecular levels. Hyp-
oxia enhanced in vitro clonogenicity, migration, inva-
sion, and drug resistance to cisplatin in HMM cells.
Various signaling pathways and molecular targets were
associated with the hypoxia-induced aggressive behav-
iors, including HIF-1/2α, EMT, Oct4, and anti-apoptotic
Bcl-2. The data presented in this study emphasize the
clinical importance of hypoxia in the biology of HMM.
Exploiting molecular signaling pathways affected by the
hypoxia may help to overcome the low efficacy of trad-
itional anticancer therapy for HMM patients.
In the present study, hypoxia enhanced the in vitro col-
ony forming capability of HMM cells. Bcl-2 antagoniza-
tion reduces in vitro clonogenicity through apoptosis
induction [24, 25]. In this context, the present study
showed that the increased Bcl-2 activity likely provided an
additional survival advantage to individual HMM cells
during colony formation in hypoxia. The effect of hypoxia
on the proliferation of HMM cells in culture condition
has been reported [26]. Hypoxia enhances tumor stemness
by reprogramming non-stem cancer cells to be cancer
stem cells (CSCs) with tumor-initiating capacity [27]. The
increase of cells with high CD44 expression supports the
notion that hypoxia enhanced the stemness of HMM cells
[22, 23]. The transformation to CSCs is through the activa-
tion of HIFα and stemness-related transcriptional factors,
including Oct4, c-Myc, and Notch [27]. In the present
study, the enhanced clonogenicity of HMM cells might be
associated with increased Oct4 expression, which was me-
diated through the transcriptional activity of HIF-2α. The
upregulation of Oct4 at mRNA level in hypoxic condition
contributes to the formation of more viable colonies with
different origins of CSCs [28–30]. Heddleston et al. [31]
demonstrated the functional significance of HIF-2α and
Oct4 in the maintenance of the CSC state under hypoxia.
The weak correlation between Oct4 mRNA and protein
expression may suggest the involvement of post-transcrip-
tional modification of Oct4 and/or another stemness fac-
tors in enhancing the clonogenicity of HMM cells under
hypoxia [32]. CSC factors like c-Myc or Notch are tightly
regulated together with Oct4 by the competitive cooper-
ation of HIF-1α and HIF-2α in hypoxic tumor cells [33,
34]. Further studies are warranted to elucidate the func-
tional relationship between HIFαs and stem cell factors in-
cluding Oct4 in HMM cells. On the other hand, in the
present study, once the HMM cells proliferated in high cell
populations after completing colony formation, cell growth
was decelerated by hypoxia. This phenomenon may be at-
tributable to the insufficient supply of energy required for
cellular proliferation under hypoxia. One of the principal
Fig. 6 The effect of hypoxia on migration and invasion in HMM cells. (a) Hypoxia significantly increased migration in HMM cells. (b) Hypoxia
significantly enhanced invasion in H513 cells. (c) Phase contrast images (400× magnification) of HMM cells cultured for 48 h under normoxia or
hypoxia are presented. (d) Hypoxia induced a loss of E-cadherin expression and a gain of vimentin expression in HMM cells. E-cadherin expression was
not detected in MS1 cells. *P value < 0.05, as calculated by Student’s t-test
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actions of HIF-1α is to shift tumor metabolism from oxida-
tive phosphorylation to anaerobic glycolysis [8]. The hyp-
oxic cancer cells consume more glucose by augmenting
glucose influx through the upregulation of glucose trans-
porters, such as Glut-1 [1, 5]. Accordingly, Glut-1 overex-
pression induced by hypoxia suggested the high energy
demand or hypoxia-associated nutrient deprivation of
HMM cells in this study. Because cell cycle arrest was not
determined in hypoxia in this study, the process of protein
synthesis could be inhibited, resulting in the decelerated
proliferation of HMM cells, as previously suggested [26].
An acquired apoptosis resistance is closely associ-
ated with ineffective cancer therapy [3]. Hypoxia in-
hibits apoptosis in many cancer types following drug
treatment [35]. The present study showed that HMM
cells acquired a drug-resistant phenotype through in-
hibition of cisplatin-induced apoptosis under hypoxia.
In particular, alteration of Bcl-2 might be responsible
for the hypoxia-induced chemoresistance in HMM
cells. The Bcl-2 family is a potential blocker of apop-
tosis and plays a key role in the drug resistance of
multiple tumor types [36]. The anti-apoptosis by
Bcl-2 is largely due to the inhibition of mitochondrial
membrane permeabilization, which can also be acti-
vated by pro-apoptotic molecules upon various stimuli
that initiate apoptosis [37]. Due to its hydrophobic
BH3 binding groove, Bcl-2 engages in multiple anti-
and pro-apoptotic Bcl-2 protein-protein interactions,
i.e., by binding and sequestering the pro-apoptotic
Bax [37]. In this context, the increase of Bcl-2 expres-
sion relative to Bax may represent an aspect of
hypoxia-induced drug resistance involved in mito-
chondrial protection upon exposure to cisplatin in
HMM cells. In the present study, the role of Bcl-xL
in promoting drug resistance under hypoxia is un-
clear. The inability of H513 cells to induce Bax ex-
pression in response to external stimuli may be
attributable to the p53 mutation. It has been reported
that tumor cells with mutant p53 do not induce Bax
expression upon apoptotic stimuli [38]. This is con-
sistent with the previous findings that H513 cells
failed to induce Bax expression during TNF-related
apoptosis-inducing ligand-mediated apoptosis induced
by a histone deacetylase inhibitor [39].
Similar to the previous study [40], hypoxia enhanced the
migratory and invasive properties in HMM cells. Addition-
ally, the present study showed that hypoxia promoted EMT
process in HMM cells. In HMM, it was shown that the
miR-205-mediated reduction of ZEB1 and ZEB2 increased
the expression of E-cadherin, which inhibited migration
and invasion [41]. The EMT is closely associated with hyp-
oxia and is regulating a more aggressive behavior of cancer
cells [42]. In HMM carcinogenesis, HIF-1α stabilization
promotes EMT process and stemness via an increased
expression of TGF-β and stem cell factors [21]. Moreover,
EMT is associated with the emergence of CSCs in HMM
cells [43]. Tumor hypoxia is known to recapitulate the
HMM microenvironment of the body cavity with HIF-1α
expression, and EMT has been potentially implicated in
mesothelial carcinogenesis [44, 45]. HIF-1α regulates the
expression of a variety of genes involved in EMT-triggering
pathways, including TGF-β, Notch, and NF-κB, and
EMT-promoting transcription factors, including Twist,
Snail, Slug, and, Sip [42]. In the same vein, HIF-2α is also
implicated in the stimulation of EMT-related factors, such
as E-cadherin, LOX, CXCR4, Twist, and Zeb1 [7, 9, 42]. On
the other hand, a published study showed that hypoxia in-
duced mesenchymal to epithelial transition through the ac-
tivation of HIF-2α in MSTO-211H cells, an HMM cell line
[46]. Cell types and experimental conditions may be re-
sponsible for the distinct response to hypoxia with regard
to the phenotypic change. Although further studies are re-
quired to determine the underlying mechanisms, EMT
phenotypes under hypoxia can shed light on understanding
how the hypoxic microenvironment governs the malignant
progression of HMM.
Conclusion
Like other tumors, HMM contains significant areas of
hypoxia, but little information is available on the rela-
tionship between hypoxia and tumor aggressiveness. The
present study illustrated the importance of hypoxia in the
progression of HMM cells. Understanding the signaling
pathways and molecular mechanisms affected by hyp-
oxia may contribute to the development of therapeutic
strategies targeting the microenvironmental influence on
HMM biology.
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